Tenaya Therapeutics (TNYA)
(Real Time Quote from BATS)
$2.95 USD
+0.23 (8.46%)
Updated Aug 13, 2024 12:56 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Tenaya Therapeutics, Inc. (TNYA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.43 | $40.00 | $8.00 | 614.34% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Tenaya Therapeutics, Inc. comes to $19.43. The forecasts range from a low of $8.00 to a high of $40.00. The average price target represents an increase of 614.34% from the last closing price of $2.72.
Analyst Price Targets (7 )
Broker Rating
Tenaya Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TNYA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/8/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
6/10/2024 | William Blair | Sami Corwin | Not Available | Strong Buy |
5/15/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
5/15/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
5/15/2024 | LifeSci Capital | Cory Jubinville | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/20/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
3/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $19.43 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 253 |
Current Quarter EPS Est: | -0.37 |